{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:21:29Z","timestamp":1773030089541,"version":"3.50.1"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biophysical Chemistry"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bpc.2022.106824","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T22:13:07Z","timestamp":1652307187000},"page":"106824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects"],"prefix":"10.1016","volume":"288","author":[{"given":"Samira","family":"Mahmoudi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad Mohammadpour","family":"Dehkordi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hossein","family":"Asgarshamsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1573405617666210414101941","article-title":"Corona virus-related disease pandemic: a review on machine learning approaches and treatment trials on diagnosed population for future clinical decision support","volume":"18","author":"Reyana","year":"2022","journal-title":"Curr. Med. Imaging."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/molecules26010039","article-title":"COVID-19: a global challenge with old history, epidemiology and progress so far","volume":"26","author":"Khan","year":"2021","journal-title":"Molecules."},{"issue":"6551","key":"10.1016\/j.bpc.2022.106824_bb0015","doi-asserted-by":"crossref","first-page":"eabi5273","DOI":"10.1126\/science.abi5273","article-title":"Estimating infectiousness throughout SARS-CoV-2 infection course","volume":"373","author":"Jones","year":"2021","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12038-021-00145-7","article-title":"SARS-CoV-2 genomics: an Indian perspective on sequencing viral variants","volume":"46","author":"Srivastava","year":"2021","journal-title":"J. Biosci."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0025","first-page":"107","article-title":"The novel drug discovery to combat COVID-19 by repressing important virus proteins involved in pathogenesis using medicinal herbal compounds","volume":"13","author":"Mahmoudi","year":"2021","journal-title":"Avicenna J. Med. Biotechnol."},{"issue":"9","key":"10.1016\/j.bpc.2022.106824_bb0030","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02422-20","article-title":"The polybasic cleavage site in SARS-CoV-2 spike modulates viral sensitivity to type I interferon and IFITM2","volume":"95","author":"Winstone","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.bpc.2022.106824_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2020.106425","article-title":"Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation","volume":"264","author":"Rao","year":"2020","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.bpc.2022.106824_bb0040","series-title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)","author":"Ahn","year":"2020"},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00203-021-02606-x","article-title":"COVID-19: comprehensive review on mutations and current vaccines","volume":"204","author":"Hebbani","year":"2022","journal-title":"Arch. Microbiol."},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa021","article-title":"The reproductive number of COVID-19 is higher compared to SARS coronavirus","volume":"27","author":"Liu","year":"2020","journal-title":"J. Travel Med"},{"key":"10.1016\/j.bpc.2022.106824_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109877","article-title":"Genetic variation in SARS-CoV-2 may explain variable severity of COVID-19","volume":"143","author":"Biswas","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.arcmed.2020.09.010","article-title":"Coronavirus disease (COVID-19): current status and prospects for drug and vaccine development","volume":"52","author":"Ita","year":"2021","journal-title":"Arch. Med. Res."},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40495-021-00253-w","article-title":"Efficacy and safety of new and emerging drugs for COVID-19: favipiravir and dexamethasone","volume":"7","author":"Sood","year":"2021","journal-title":"Curr. Pharmacol. Rep."},{"issue":"6965","key":"10.1016\/j.bpc.2022.106824_bb0070","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature."},{"key":"10.1016\/j.bpc.2022.106824_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2020.100407","article-title":"Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors","volume":"20","author":"Balmeh","year":"2020","journal-title":"Inform. Med. Unlocked."},{"key":"10.1016\/j.bpc.2022.106824_bb0080","author":"Fintelman-Rodrigues"},{"issue":"21","key":"10.1016\/j.bpc.2022.106824_bb0085","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: drug targets and potential treatments","volume":"63","author":"Gil","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: a systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.bpc.2022.106824_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijbiomac.2021.02.071","article-title":"Potential drug targets of SARS-CoV-2: from genomics to therapeutics","volume":"177","author":"Shamsi","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"7807","key":"10.1016\/j.bpc.2022.106824_bb0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature."},{"issue":"5742","key":"10.1016\/j.bpc.2022.106824_bb0105","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0110","doi-asserted-by":"crossref","first-page":"17699","DOI":"10.1038\/s41598-020-74715-4","article-title":"Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2","volume":"10","author":"Basu","year":"2020","journal-title":"Sci. Rep."},{"issue":"6573","key":"10.1016\/j.bpc.2022.106824_bb0115","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1126\/science.abl9463","article-title":"Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant","volume":"374","author":"Zhang","year":"2021","journal-title":"Science."},{"issue":"5","key":"10.1016\/j.bpc.2022.106824_bb0120","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","article-title":"Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity","volume":"184","author":"Thomson","year":"2021","journal-title":"Cell."},{"key":"10.1016\/j.bpc.2022.106824_bb0125","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.bbrc.2020.11.075","article-title":"Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity","volume":"534","author":"Chakraborty","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bpc.2022.106824_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2021.114424","article-title":"Screening of potential spike glycoprotein \/ ACE2 dual antagonists against COVID-19 in silico molecular docking","volume":"301","author":"Yu","year":"2022","journal-title":"J. Virol. Methods"},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0135","article-title":"Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM","volume":"7","author":"Xu","year":"2020","journal-title":"bioRxiv"},{"issue":"8","key":"10.1016\/j.bpc.2022.106824_bb0140","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.emboj.7600640","article-title":"Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2","volume":"24","author":"Li","year":"2005","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41594-020-00549-3","article-title":"A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent","volume":"28","author":"Xiao","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.compbiolchem.2005.04.008","article-title":"A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2","volume":"29","author":"Zhang","year":"2005","journal-title":"Comput. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bpc.2022.106824_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001237","article-title":"Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies","volume":"19","author":"Zhu","year":"2021","journal-title":"PLoS Biol."},{"issue":"6555","key":"10.1016\/j.bpc.2022.106824_bb0160","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.abi9745","article-title":"Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants","volume":"373","author":"Cai","year":"2021","journal-title":"Science."},{"issue":"12","key":"10.1016\/j.bpc.2022.106824_bb0165","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00228-020-02963-4","article-title":"Inhibition of SARS-CoV-2 entry through the ACE2\/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies","volume":"76","author":"Ragia","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension."},{"key":"10.1016\/j.bpc.2022.106824_bb0175","series-title":"Mayo Clinic Proceedings","article-title":"Angiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus disease 2019","author":"Sanchis-Gomar","year":"2020"},{"issue":"227","key":"10.1016\/j.bpc.2022.106824_bb0180","article-title":"Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the hACE2 receptor","volume":"9","author":"Al-Karmalawy","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.bpc.2022.106824_bb0185","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/jocs.14582","article-title":"ACE inhibitors and COVID-19: we don\u2019t know yet","author":"Khashkhusha","year":"2020","journal-title":"J. Card. Surg."},{"issue":"6","key":"10.1016\/j.bpc.2022.106824_bb0190","first-page":"516","article-title":"Controversy regarding ACE inhibitors\/ARBs in COVID-19","volume":"73","author":"Arcos","year":"2020","journal-title":"Revista Esp. Cardiol. (Engl. ed)."},{"issue":"19","key":"10.1016\/j.bpc.2022.106824_bb0195","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1136\/heartjnl-2020-317393","article-title":"Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people","volume":"106","author":"Hippisley-Cox","year":"2020","journal-title":"Heart."},{"issue":"43","key":"10.1016\/j.bpc.2022.106824_bb0200","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bpc.2022.106824_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107750","article-title":"A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor","volume":"221","author":"Oz","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.bpc.2022.106824_bb0210","first-page":"3263","article-title":"In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria","volume":"39","author":"Abdelli","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bpc.2022.106824_bb0215","article-title":"Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2","volume":"1-17","author":"Khelfaoui","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3602","key":"10.1016\/j.bpc.2022.106824_bb0220","article-title":"Molecular docking reveals ivermectin and remdesivir as potential repurposed drugs against SARS-CoV-2","volume":"11","author":"Eweas","year":"2021","journal-title":"Front. Microbiol."},{"issue":"9","key":"10.1016\/j.bpc.2022.106824_bb0225","first-page":"3263","article-title":"In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria","volume":"39","author":"Abdelli","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bpc.2022.106824_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.661230","article-title":"Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the hACE2 receptor","volume":"9","author":"Al-Karmalawy","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.bpc.2022.106824_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108117","article-title":"Negative allosteric modulation of GluN1\/GluN3 NMDA receptors","volume":"176","author":"Zhu","year":"2020","journal-title":"Neuropharmacology."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0240","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41598-018-19642-1","article-title":"The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions","volume":"8","author":"Draper-Joyce","year":"2018","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.bpc.2022.106824_bb0245","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1080\/07391102.2020.1792993","article-title":"Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study","volume":"39","author":"Cel\u0131","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bpc.2022.106824_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2021.100714","article-title":"A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection","volume":"26","author":"Navya","year":"2021","journal-title":"Inform. Med. Unlocked."},{"issue":"15","key":"10.1016\/j.bpc.2022.106824_bb0255","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1080\/07391102.2020.1792993","article-title":"Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study","volume":"39","author":"Celik","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0260","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1038\/s41467-021-23533-x","article-title":"Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1","volume":"12","author":"Chai","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bpc.2022.106824_bb0265","series-title":"Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: The Screening for Inhibitors in Approved Drugs","author":"Chernyshev","year":"2020"},{"key":"10.1016\/j.bpc.2022.106824_bb0270","series-title":"SARS-CoV-2 Envelope Protein Induces Membrane Curvature through Asymmetric Hydrophobic Mismatch: Rutgers","author":"Sandberg","year":"2021"},{"issue":"17","key":"10.1016\/j.bpc.2022.106824_bb0275","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1111\/febs.15881","article-title":"Host PDZ-containing proteins targeted by SARS-CoV-2","volume":"288","author":"Caillet-Saguy","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.bpc.2022.106824_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2020.104063","article-title":"In silico identification of tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor","volume":"127","author":"Dey","year":"2020","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-23533-x","article-title":"Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1","volume":"12","author":"Chai","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bpc.2022.106824_bb0290","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/pro.3936","article-title":"Comparing the binding properties of peptides mimicking the envelope protein of SARS-CoV and SARS-CoV-2 to the PDZ domain of the tight junction-associated PALS1 protein","volume":"29","author":"Toto","year":"2020","journal-title":"Protein Sci."},{"key":"10.1016\/j.bpc.2022.106824_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2020.106452","article-title":"Host-membrane interacting interface of the SARS coronavirus envelope protein: immense functional potential of C-terminal domain","volume":"266","author":"Mukherjee","year":"2020","journal-title":"Biophys. Chem."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0300","doi-asserted-by":"crossref","first-page":"827","DOI":"10.5114\/aoms\/134716","article-title":"Could amantadine possibly interfere with COVID-19 vaccines based on LNP-mRNA platform?","volume":"17","author":"Fedorowski","year":"2021","journal-title":"Arch. Med. Sci."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0305","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.virol.2004.09.033","article-title":"SARS coronavirus E protein forms cation-selective ion channels","volume":"330","author":"Wilson","year":"2004","journal-title":"Virology."},{"issue":"4","key":"10.1016\/j.bpc.2022.106824_bb0310","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/v13040539","article-title":"Amantadine inhibits SARS-CoV-2 in vitro","volume":"13","author":"Fink","year":"2021","journal-title":"Viruses."},{"key":"10.1016\/j.bpc.2022.106824_bb0315","series-title":"Amantadin Has Potential for the Treatment of COVID-19 because it Targets Known and Novel Ion Channels Encoded by SARS-CoV-2","author":"Jeppesen","year":"2020"},{"issue":"6","key":"10.1016\/j.bpc.2022.106824_bb0320","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/acsptsci.0c00172","article-title":"Docking prediction of amantadine in the receptor binding domain of spike protein of SARS-CoV-2","volume":"3","author":"Baig","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0325","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbrc.2020.05.206","article-title":"SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine","volume":"530","author":"Singh Tomar","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bpc.2022.106824_bb0330","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5582\/ddt.2020.03070","article-title":"Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?","volume":"14","author":"Adil","year":"2020","journal-title":"Drug Discov. Ther."},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0335","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.virol.2006.05.028","article-title":"Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication","volume":"353","author":"Wilson","year":"2006","journal-title":"Virology."},{"issue":"7","key":"10.1016\/j.bpc.2022.106824_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000511","article-title":"Structure and inhibition of the SARS coronavirus envelope protein ion channel","volume":"5","author":"Pervushin","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bpc.2022.106824_bb0345","series-title":"Flawed Methods in \u201cCOVID-19: Attacks the 1-beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism\u201d","author":"Read","year":"2020"},{"key":"10.1016\/j.bpc.2022.106824_bb0350","series-title":"Inhibition of SARS-CoV-2 Envelope Ion Channel and the Relationship with the Membrane Dipole Potential","author":"Fong","year":"2021"},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0355","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbrc.2020.05.206","article-title":"SARS-CoV-2 E protein is a potential ion channel that can be inhibited by gliclazide and memantine","volume":"530","author":"Singh Tomar","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bpc.2022.106824_bb0360","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.50850.3","article-title":"Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches","volume":"10","author":"Selvaraj","year":"2021","journal-title":"F1000Res."},{"key":"10.1016\/j.bpc.2022.106824_bb0365","first-page":"1","article-title":"Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates","author":"Wang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0370","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40268-021-00351-6","article-title":"Potential for the repurposing of adamantane antivirals for COVID-19","volume":"21","author":"Butterworth","year":"2021","journal-title":"Drugs R&D."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0375","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3844\/ajbbsp.2014.180.188","article-title":"Docking and molecular dynamics (MD) simulations in potential drugs discovery: an application to influenza virus M2 protein","volume":"10","author":"Bozdaganyan","year":"2014","journal-title":"Am. J. Biochem. Biotech."},{"issue":"11","key":"10.1016\/j.bpc.2022.106824_bb0380","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1080\/07391102.2020.1774419","article-title":"A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem)","volume":"39","author":"Borkotoky","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/v13030532","article-title":"Blockers of the SARS-CoV-2 3a channel identified by targeted drug repurposing","volume":"13","author":"Tomar","year":"2021","journal-title":"Viruses."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43141-021-00120-7","article-title":"Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus","volume":"19","author":"Umar","year":"2021","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"10.1016\/j.bpc.2022.106824_bb0395","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1016\/j.csbj.2021.08.036","article-title":"An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CLpro\/Mpro) of SARS-CoV-2","volume":"19","author":"Yan","year":"2021","journal-title":"Computat. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat. Commun."},{"issue":"7835","key":"10.1016\/j.bpc.2022.106824_bb0405","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.bpc.2022.106824_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.594009","article-title":"Repurposing known drugs as covalent and non-covalent inhibitors of the SARS-CoV-2 papain-like protease","volume":"8","author":"Delre","year":"2020","journal-title":"Front. Chem."},{"issue":"30","key":"10.1016\/j.bpc.2022.106824_bb0415","doi-asserted-by":"crossref","first-page":"21512","DOI":"10.18632\/oncotarget.25177","article-title":"Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase","volume":"9","author":"Yu","year":"2018","journal-title":"Oncotarget."},{"issue":"47","key":"10.1016\/j.bpc.2022.106824_bb0420","doi-asserted-by":"crossref","first-page":"28287","DOI":"10.1039\/D0RA04395H","article-title":"Targeting severe acute respiratory syndrome-coronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review","volume":"10","author":"Hosseini-Zare","year":"2020","journal-title":"RSC Adv."},{"issue":"4","key":"10.1016\/j.bpc.2022.106824_bb0425","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/095632020901900402","article-title":"Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme","volume":"19","author":"Chen","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0430","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acsptsci.1c00240","article-title":"Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors","volume":"5","author":"Ma","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"18","key":"10.1016\/j.bpc.2022.106824_bb0435","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.bpc.2022.106824_bb0440","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.bcp.2008.01.005","article-title":"Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus","volume":"75","author":"Chou","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0445","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/prot.22327","article-title":"Geometric characteristics of hydrogen bonds involving sulfur atoms in proteins","volume":"76","author":"Zhou","year":"2009","journal-title":"Proteins."},{"issue":"5626","key":"10.1016\/j.bpc.2022.106824_bb0450","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0455","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.antiviral.2011.08.001","article-title":"Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease","volume":"92","author":"Zhu","year":"2011","journal-title":"Antivir. Res."},{"issue":"42","key":"10.1016\/j.bpc.2022.106824_bb0460","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti\u2013COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.bpc.2022.106824_bb0465","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development","volume":"19","author":"Yang","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.bpc.2022.106824_bb0470","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1189\/jlb.1206727","article-title":"MD-2 as the target of curcumin in the inhibition of response to LPS","volume":"82","author":"Gradi\u0161ar","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bpc.2022.106824_bb0475","doi-asserted-by":"crossref","first-page":"e9965","DOI":"10.7717\/peerj.9965","article-title":"Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs","volume":"8","author":"Kouznetsova","year":"2020","journal-title":"PeerJ."},{"issue":"4","key":"10.1016\/j.bpc.2022.106824_bb0480","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12154-013-0099-0","article-title":"Molecular recognition with boronic acids-applications in chemical biology","volume":"6","author":"Whyte","year":"2013","journal-title":"J. Chem. Biol."},{"issue":"4","key":"10.1016\/j.bpc.2022.106824_bb0485","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12154-013-0099-0","article-title":"Molecular recognition with boronic acids-applications in chemical biology","volume":"6","author":"Whyte","year":"2013","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.bpc.2022.106824_bb0490","series-title":"Gliptin Repurposing for COVID-19","author":"Groves","year":"2020"},{"key":"10.1016\/j.bpc.2022.106824_bb0495","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.bpc.2022.106824_bb0500","doi-asserted-by":"crossref","first-page":"e05558","DOI":"10.1016\/j.heliyon.2020.e05558","article-title":"Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19","volume":"6","author":"Bhati","year":"2020","journal-title":"Heliyon."},{"issue":"36","key":"10.1016\/j.bpc.2022.106824_bb0505","doi-asserted-by":"crossref","first-page":"9904","DOI":"10.1039\/D0SC02646H","article-title":"Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors","volume":"11","author":"Sargsyan","year":"2020","journal-title":"Chem. Sci."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0510","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/molecules27030658","article-title":"Approaches to the potential therapy of COVID-19: a general overview from the medicinal chemistry perspective","volume":"27","author":"Men\u00e9ndez","year":"2022","journal-title":"Molecules."},{"issue":"7811","key":"10.1016\/j.bpc.2022.106824_bb0515","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.bpc.2022.106824_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.622898","article-title":"Structural basis of potential inhibitors targeting SARS-CoV-2 main protease","volume":"9","author":"Mengist","year":"2021","journal-title":"Front. Chem."},{"issue":"21","key":"10.1016\/j.bpc.2022.106824_bb0525","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1021\/ja00047a004","article-title":"Attack of zwitterionic ammonium thiolates on a distorted anilide as a model for the acylation of papain by amides. A simple demonstration of a bell-shaped pH\/rate profile","volume":"114","author":"Keillor","year":"1992","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.bpc.2022.106824_bb0530","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.peptides.2004.06.018","article-title":"Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide","volume":"25","author":"Du","year":"2004","journal-title":"Peptides."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/abio.1996.0001","article-title":"Prediction of human immunodeficiency virus protease cleavage sites in proteins","volume":"233","author":"Chou","year":"1996","journal-title":"Anal. Biochem."},{"issue":"7","key":"10.1016\/j.bpc.2022.106824_bb0540","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1021\/acs.jmedchem.0c01808","article-title":"The alpha keto amide moiety as a privileged motif in medicinal chemistry: current insights and emerging opportunities","volume":"64","author":"Robello","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6489","key":"10.1016\/j.bpc.2022.106824_bb0545","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science (New York, N.Y.)"},{"issue":"9","key":"10.1016\/j.bpc.2022.106824_bb0550","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bpc.2022.106824_bb0555","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0560","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cben.201400031","article-title":"Characterization and inhibition of the main protease of severe acute respiratory syndrome coronavirus","volume":"2","author":"Kuo","year":"2015","journal-title":"ChemBioEng Rev."},{"key":"10.1016\/j.bpc.2022.106824_bb0565","article-title":"A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells","author":"Mellott","year":"2020","journal-title":"bioRxiv Preprint Server Biol"},{"key":"10.1016\/j.bpc.2022.106824_bb0570","unstructured":"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors."},{"issue":"24","key":"10.1016\/j.bpc.2022.106824_bb0575","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1021\/ja00284a004","article-title":"Theoretical determination of molecular structure and conformation. 20. Reevaluation of the strain energies of cyclopropane and cyclobutane carbon-carbon and carbon-hydrogen bond energies, 1, 3 interactions, and sigma-aromaticity","volume":"108","author":"Cremer","year":"1986","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0580","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/med.21724","article-title":"The recent outbreaks of human coronaviruses: a medicinal chemistry perspective","volume":"41","author":"Pillaiyar","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0585","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s11030-020-10166-3","article-title":"First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery","volume":"25","author":"Amin","year":"2021","journal-title":"Mol. Divers."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0590","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/ijms22031398","article-title":"Pseudo-dipeptide bearing \u03b1,\u03b1-difluoromethyl ketone moiety as electrophilic warhead with activity against coronaviruses","volume":"22","author":"Citarella","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6497","key":"10.1016\/j.bpc.2022.106824_bb0595","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science (New York, N.Y.)"},{"issue":"30","key":"10.1016\/j.bpc.2022.106824_bb0600","doi-asserted-by":"crossref","first-page":"8744","DOI":"10.1021\/bi0621415","article-title":"Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus","volume":"46","author":"Goetz","year":"2007","journal-title":"Biochemistry."},{"issue":"167","key":"10.1016\/j.bpc.2022.106824_bb0605","article-title":"Plant products as inhibitors of coronavirus 3CL protease","volume":"12","author":"Mandal","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"13","key":"10.1016\/j.bpc.2022.106824_bb0610","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1080\/07391102.2020.1782768","article-title":"Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro","volume":"39","author":"Alamri","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bpc.2022.106824_bb0615","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1039\/b705034h","article-title":"Sulfonyl vs. carbonyl group: which is the more electron-withdrawing?","volume":"31","author":"Chataigner","year":"2007","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bpc.2022.106824_bb0620","article-title":"Potentially highly potent drugs for 2019-nCoV","author":"Nguyen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.bpc.2022.106824_bb0625","series-title":"Pharmacoinformatics and molecular dynamic simulation studies reveal potential inhibitors of SARS-CoV-2 main protease 3CLpro","author":"Alamri","year":"2020"},{"issue":"419","key":"10.1016\/j.bpc.2022.106824_bb0630","article-title":"Identification of potential inhibitors of 3CL protease of SARS-CoV-2 from ZINC database by molecular docking-based virtual screening","volume":"7","author":"Abdusalam","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"9","key":"10.1016\/j.bpc.2022.106824_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07962","article-title":"Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies","volume":"7","author":"Mahmoud","year":"2021","journal-title":"Heliyon."},{"issue":"12","key":"10.1016\/j.bpc.2022.106824_bb0640","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1021\/acsmedchemlett.0c00521","article-title":"Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2","volume":"11","author":"Ghahremanpour","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"Suppl. 2","key":"10.1016\/j.bpc.2022.106824_bb0645","first-page":"25","article-title":"Analysis of the molecular activity of atazanavir against SARS-COV-2 by molecular docking studies","volume":"1","author":"Ara\u00fajo","year":"2021","journal-title":"Acta Scient. Anat."},{"key":"10.1016\/j.bpc.2022.106824_bb0650","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Computat. Struct. Biotechnol. J."},{"key":"10.1016\/j.bpc.2022.106824_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.105183","article-title":"Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: molecular insights into improved therapeutic discovery","volume":"142","author":"Ray","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bpc.2022.106824_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.599079","article-title":"In silico screening of natural compounds as potential inhibitors of SARS-CoV-2 Main protease and spike RBD: targets for COVID-19","volume":"7","author":"Teli","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"14","key":"10.1016\/j.bpc.2022.106824_bb0665","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1080\/07391102.2020.1784291","article-title":"Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease","volume":"39","author":"Kandeel","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"72","key":"10.1016\/j.bpc.2022.106824_bb0670","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1039\/D1CC03953A","article-title":"Computational simulations on the binding and reactivity of a nitrile inhibitor of the SARS-CoV-2 main protease","volume":"57","author":"Ramos-Guzm\u00e1n","year":"2021","journal-title":"Chem. Commun."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02439-0","article-title":"Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach","volume":"18","author":"Aftab","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bpc.2022.106824_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2021.100515","article-title":"Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease","volume":"23","author":"Balmeh","year":"2021","journal-title":"Inform. Med. Unlocked."},{"key":"10.1016\/j.bpc.2022.106824_bb0685","series-title":"Biomedical Innovations to Combat COVID-19","first-page":"65","article-title":"Structural biology of the SARS-CoV-2 replisome: evolutionary and therapeutic implications","author":"Hern\u00e1ndez-Morales","year":"2022"},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0690","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/jmv.26264","article-title":"RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target","volume":"93","author":"Wang","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bpc.2022.106824_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bpc.2022.106824_bb0700","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2020.08.116","article-title":"RNA-dependent RNA polymerase: structure, mechanism, and drug discovery for COVID-19","volume":"538","author":"Jiang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"05","key":"10.1016\/j.bpc.2022.106824_bb0705","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bsheal.2021.07.003","article-title":"SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: a review","volume":"3","author":"Muhammed","year":"2021","journal-title":"Biosafety Health."},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0710","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural basis for RNA replication by the SARS-CoV-2 polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.bpc.2022.106824_bb0715","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.13005\/bpj\/2304","article-title":"Polyamidoamine-remdesivir conjugate: physical stability and cellular uptake enhancement","author":"Qudsiani","year":"2021","journal-title":"Biomed. Pharmacol. J."},{"issue":"32","key":"10.1016\/j.bpc.2022.106824_bb0720","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1021\/acs.jpcb.0c04198","article-title":"Structural basis of the potential binding mechanism of remdesivir to SARS-CoV-2 RNA-dependent RNA polymerase","volume":"124","author":"Zhang","year":"2020","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bpc.2022.106824_bb0725","article-title":"SARS-CoV-2: origin, evolution, and targeting inhibition. Frontiers in cellular and infection","volume":"11","author":"Ning","year":"2021","journal-title":"Microbiology."},{"key":"10.1016\/j.bpc.2022.106824_bb0730","first-page":"1","article-title":"Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2","author":"Mishra","year":"2022","journal-title":"Mol. Divers."},{"issue":"16","key":"10.1016\/j.bpc.2022.106824_bb0735","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1016\/j.bmcl.2013.06.045","article-title":"Tetrazole and triazole as bioisosteres of carboxylic acid: discovery of diketo tetrazoles and diketo triazoles as anti-HCV agents","volume":"23","author":"Song","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bpc.2022.106824_bb0740","doi-asserted-by":"crossref","first-page":"649","DOI":"10.52142\/omujecm.38.4.44","article-title":"Epidemiology, virology, clinical features, diagnosis, and treatment of SARS-CoV-2 infection","volume":"38","author":"Mahmoudi","year":"2021","journal-title":"J. Exp. Clin. Med."},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0745","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr. Comput. Aided Drug Des."},{"issue":"9","key":"10.1016\/j.bpc.2022.106824_bb0750","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.hrthm.2020.07.001","article-title":"Prophylactic (hydroxy) chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk","volume":"17","author":"Offerhaus","year":"2020","journal-title":"Heart Rhythm."},{"issue":"11","key":"10.1016\/j.bpc.2022.106824_bb0755","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12471-020-01506-x","article-title":"QTc interval prolongation, COVID-19 and chloroquine","volume":"28","author":"Wiwanitkit","year":"2020","journal-title":"Neth. Hear. J."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0760","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s42003-022-03090-9","article-title":"Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay","volume":"5","author":"Narayanan","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bpc.2022.106824_bb0765","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.819165","article-title":"Targeting SARS-CoV-2 proteases for COVID-19 antiviral development","volume":"9","author":"Lv","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.bpc.2022.106824_bb0770","series-title":"Theoretical Evaluation of Bortezomib and Other Boron-Containing Compounds as Inhibitors of SARS-CoV-2 Main Protease","author":"Valdez","year":"2020"},{"issue":"2","key":"10.1016\/j.bpc.2022.106824_bb0775","first-page":"240","article-title":"Painful blisters of left hand following extravasation of remdesivir infusion in COVID-19","volume":"25","author":"Kumar","year":"2021","journal-title":"Indian J. Critic. Care Med. Peer-rev. Off. Publ. Indian Soc. Critic. Care Med."},{"issue":"9","key":"10.1016\/j.bpc.2022.106824_bb0780","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.bpc.2022.106824_bb0785","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/ijms23031508","article-title":"Computational analysis of molnupiravir","volume":"23","author":"Sharov","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bpc.2022.106824_bb0790","article-title":"Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection","volume":"1-14","author":"Akbarzadeh-Khiavi","year":"2021","journal-title":"Infection."},{"key":"10.1016\/j.bpc.2022.106824_bb0795","doi-asserted-by":"crossref","first-page":"104365","DOI":"10.1016\/j.micpath.2020.104365","article-title":"Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease","volume":"148","author":"Marinho","year":"2020","journal-title":"Microb. Pathog."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0800","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U","article-title":"The hydrogen bond in the solid state","volume":"41","author":"Steiner","year":"2002","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.bpc.2022.106824_bb0805","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3762\/bjoc.9.179","article-title":"A Lewis acid-promoted pinner reaction","volume":"9","author":"Pfaff","year":"2013","journal-title":"Beilstein J. Org. Chem."},{"issue":"5","key":"10.1016\/j.bpc.2022.106824_bb0810","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201312","article-title":"A virus that has gone viral: amino acid mutation in S protein of Indian isolate of coronavirus COVID-19 might impact receptor binding, and thus, infectivity","volume":"40","author":"Saha","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bpc.2022.106824_bb0815","series-title":"Artemisinin and Quinoline Hybrid Compounds Inhibit Replication of SARS-CoV-2 in Vitro","author":"Herrmann","year":"2021"},{"key":"10.1016\/j.bpc.2022.106824_bb0820","first-page":"266","article-title":"COVID-19 drug design based on the active Core of well-known anti-malarial: a computational approaches","volume":"6","author":"Najar","year":"2020","journal-title":"J. Theor. Comput. Sci."},{"issue":"9","key":"10.1016\/j.bpc.2022.106824_bb0825","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.hrthm.2020.05.008","article-title":"QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review","volume":"17","author":"Jankelson","year":"2020","journal-title":"Heart Rhythm."},{"issue":"5","key":"10.1016\/j.bpc.2022.106824_bb0830","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/molecules22050710","article-title":"Adamantane-isothiourea hybrid derivatives: synthesis, characterization, in vitro antimicrobial, and in vivo hypoglycemic activities","volume":"22","author":"Al-Wahaibi","year":"2017","journal-title":"Mol. (Basel, Switzerland)."}],"container-title":["Biophysical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301462222000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301462222000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T07:58:05Z","timestamp":1759564685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301462222000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":166,"alternative-id":["S0301462222000667"],"URL":"https:\/\/doi.org\/10.1016\/j.bpc.2022.106824","relation":{},"ISSN":["0301-4622"],"issn-type":[{"value":"0301-4622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects","name":"articletitle","label":"Article Title"},{"value":"Biophysical Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpc.2022.106824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106824"}}